Mechanism of statin-associated mortality reduction in COPD [7]

Chest

Volumn 132, Issue 4, 2007, Pages 1409-

  Hurst, John R ^a   Hagan, Gerry ^b   Wedzicha, Jadwiga A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6;

ADULT; AGED; ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COMORBIDITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG MECHANISM; FORCED EXPIRATORY VOLUME; HEART INFARCTION; HUMAN; LETTER; MAJOR CLINICAL STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SYSTEMIC DISEASE;

EID: 35448938050     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-1435     Document Type: Letter

References (3)

1. Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007; 131:1006-1012
2. Hothersall E, McSharry C, Thomson NC, et al. Potential therapeutic role for statins in respiratory disease. Thorax 2006; 61:729-734
3. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:867-874